AngioDynamics (ANGO) Earns Daily News Impact Rating of 0.20
Media stories about AngioDynamics (NASDAQ:ANGO) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AngioDynamics earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 46.4162264863515 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Outcomes in a Nurse-Led Peripherally Inserted Central Catheter Program: A Retrospective Cohort Study Published in CMAJ Open (finance.yahoo.com)
- AngioDynamics to Report Fiscal 2018 First Quarter Financial Results (feeds.benzinga.com)
- AngioDynamics to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference (finance.yahoo.com)
Several analysts have recently weighed in on ANGO shares. Canaccord Genuity reissued a “hold” rating and issued a $16.50 price target on shares of AngioDynamics in a research note on Wednesday, May 31st. Cantor Fitzgerald increased their price target on shares of AngioDynamics from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Tuesday, July 4th. Barclays PLC dropped their price target on shares of AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 19th. Zacks Investment Research cut shares of AngioDynamics from a “hold” rating to a “sell” rating in a research note on Thursday, July 20th. Finally, BidaskClub cut shares of AngioDynamics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. AngioDynamics has an average rating of “Hold” and an average target price of $18.60.
AngioDynamics (NASDAQ:ANGO) traded up 0.72% during trading on Monday, hitting $18.09. 14,680 shares of the company were exchanged. The company has a 50-day moving average of $16.91 and a 200-day moving average of $16.30. AngioDynamics has a 12 month low of $14.80 and a 12 month high of $18.35. The company has a market capitalization of $661.73 million, a price-to-earnings ratio of 132.04 and a beta of 1.14.
AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.03. AngioDynamics had a net margin of 2.00% and a return on equity of 5.19%. The firm had revenue of $86.90 million during the quarter, compared to the consensus estimate of $90.72 million. During the same period in the previous year, the firm earned $0.19 earnings per share. AngioDynamics’s revenue was down 7.0% compared to the same quarter last year. Analysts forecast that AngioDynamics will post $0.67 EPS for the current year.
In related news, CEO James C. Clemmer bought 5,000 shares of the stock in a transaction that occurred on Friday, July 21st. The stock was purchased at an average cost of $15.79 per share, for a total transaction of $78,950.00. Following the completion of the acquisition, the chief executive officer now owns 86,683 shares in the company, valued at $1,368,724.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James C. Clemmer bought 20,000 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was bought at an average price of $15.64 per share, with a total value of $312,800.00. Following the completion of the acquisition, the chief executive officer now owns 86,683 shares of the company’s stock, valued at approximately $1,355,722.12. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 25,316 shares of company stock valued at $396,806. 1.80% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/18/angiodynamics-ango-earns-daily-news-impact-rating-of-0-20.html.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Stock Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related stocks with our FREE daily email newsletter.